Literature DB >> 25757390

Barriers to using molecularly typed minority red blood cell donors in support of chronically transfused adult patients with sickle cell disease.

Matthew S Karafin1,2, Joshua J Field1,2, Jerome L Gottschall1,2,3, Gregory A Denomme3.   

Abstract

BACKGROUND: Much effort and resources have been devoted to programs that provide transfusion support for patients with sickle cell disease (SCD). The focus of many donor programs is to prevent alloimmunization by recruiting racially matched African American donors to limit the red blood cell (RBC) antigenic differences that exist between Caucasian donors and patients with SCD. STUDY DESIGN AND METHODS: In this study, we evaluated the RBC antigen characteristics of both the recipient population with SCD and the African American donor population from 2010 to 2013. We evaluated the genotype-derived predicted antigen frequencies of the donors and compared these frequencies with those of the population supported by these units. Specific attention was given to the alloimmunization rate over the 3 years and the number of D- units provided to D+ patients.
RESULTS: We recruited 6066 African American donors during the 3-year study period with 77.3% of these donors donating no more than twice. The observed genotype-derived predicted antigen frequencies were similar to the expected frequencies, and the antigen frequencies of a cohort of 54 adult patients with SCD (p > 0.05). Twelve patients (22.2%) with SCD had alloantibodies and five of these patients developed these antibodies while receiving Rh and K antigen-matched blood during the study interval. Finally, we found that 607 (37.1%) D- units were diverted to D+ patients.
CONCLUSIONS: New recruitment and prevention strategies are needed to increase the pool of available antigen-matched RBCs and decrease alloimmunization risk for this patient population.
© 2015 AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25757390     DOI: 10.1111/trf.13037

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

1.  Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.

Authors:  Connie M Arthur; Jerry William L Allen; Hans Verkerke; Justin Yoo; Ryan P Jajosky; Kathryn Girard-Pierce; Satheesh Chonat; Patricia Zerra; Cheryl Maier; Jen Rha; Ross Fasano; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Blood Adv       Date:  2021-01-26

2.  Rhesus pieces: genotype matching of RBCs.

Authors:  Jeanne E Hendrickson; Christopher A Tormey
Journal:  Blood       Date:  2018-09-13       Impact factor: 22.113

3.  Blood Group Distribution in Switzerland - a Historical Comparison.

Authors:  Thomas Volken; Rebecca J Crawford; Soraya Amar; Edgar Mosimann; Anita Tschaggelar; Behrouz Mansouri Taleghani
Journal:  Transfus Med Hemother       Date:  2017-07-18       Impact factor: 3.747

Review 4.  Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease.

Authors:  Eric A Gehrie; Paul M Ness; Evan M Bloch; Seema Kacker; Aaron A R Tobian
Journal:  Transfusion       Date:  2017-06-26       Impact factor: 3.157

Review 5.  Genotyping Applications for Transplantation and Transfusion Management: The Emory Experience.

Authors:  Ross M Fasano; Harold Cliff Sullivan; Robert A Bray; Howard M Gebel; Erin K Meyer; Annie M Winkler; Cassandra D Josephson; Sean R Stowell; Alexander Sandy Duncan; John D Roback
Journal:  Arch Pathol Lab Med       Date:  2017-03       Impact factor: 5.534

Review 6.  Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.

Authors:  Connie M Arthur; Satheesh Chonat; Ross Fasano; Marianne E M Yee; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Transfus Med Rev       Date:  2019-10-18

7.  Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia.

Authors:  Marianne E M Yee; Cassandra D Josephson; Anne M Winkler; Jennifer Webb; Naomi L C Luban; Traci Leong; Sean R Stowell; Ross M Fasano
Journal:  Transfusion       Date:  2017-08-24       Impact factor: 3.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.